Home

è più che globale doro 3p mace inventare Finora personalità

藥學雜誌電子報146期
藥學雜誌電子報146期

Better cardiovascular outcomes of type 2 diabetic patients treated with  GLP-1 receptor agonists versus DPP-4 inhibitors in clini
Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clini

Diagnostics | Free Full-Text | miR-146a-5p, miR-223-3p and miR-142-3p as  Potential Predictors of Major Adverse Cardiac Events in Young Patients with  Acute ST Elevation Myocardial Infarction—Added Value over Left  Ventricular Myocardial Work
Diagnostics | Free Full-Text | miR-146a-5p, miR-223-3p and miR-142-3p as Potential Predictors of Major Adverse Cardiac Events in Young Patients with Acute ST Elevation Myocardial Infarction—Added Value over Left Ventricular Myocardial Work

Risk factors and goal achievement related to 3P-MACE. | Download Scientific  Diagram
Risk factors and goal achievement related to 3P-MACE. | Download Scientific Diagram

A population‐adjusted indirect comparison of cardiovascular benefits of  once‐weekly subcutaneous semaglutide and dulaglutide in the treatment of  patients with type 2 diabetes, with or without established cardiovascular  disease - Evans - 2021 -
A population‐adjusted indirect comparison of cardiovascular benefits of once‐weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease - Evans - 2021 -

Cardiovascular outcomes - Media Centre | EASD
Cardiovascular outcomes - Media Centre | EASD

JKMS :: Journal of Korean Medical Science
JKMS :: Journal of Korean Medical Science

Rationale, design, and baseline characteristics of the CArdiovascular  safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®):  a randomized, double-blind, placebo-controlled clinical trial in patients  with type 2 diabetes and high ...
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high ...

Cardiovascular outcomes trials: a paradigm shift in the current management  of type 2 diabetes. - Abstract - Europe PMC
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes. - Abstract - Europe PMC

Pharmedu
Pharmedu

Study flow chart. (Abbreviation: 3P-MACE, three point major adverse... |  Download Scientific Diagram
Study flow chart. (Abbreviation: 3P-MACE, three point major adverse... | Download Scientific Diagram

3P-MACE Event Rates in CVOTs (Placebo Groups) | Download Scientific Diagram
3P-MACE Event Rates in CVOTs (Placebo Groups) | Download Scientific Diagram

KoreaMed
KoreaMed

EMPRISE study outcomes of interest. 3P‐MACE: three‐point major... |  Download Scientific Diagram
EMPRISE study outcomes of interest. 3P‐MACE: three‐point major... | Download Scientific Diagram

CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle -  ScienceDirect
CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle - ScienceDirect

Computing and interpreting the Number Needed to Treat for Cardiovascular  Outcomes Trials | Cardiovascular Diabetology | Full Text
Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials | Cardiovascular Diabetology | Full Text

Expert Cross Talk | Lupin India | Topic: Approach of Screening  Cardiovascular Risk in T2DM Speaker: Dr. Abhamoni Baro and Dr. Chandan  Modak Disclaimer: This program is facilitated by... | By Lupin India |  Facebook
Expert Cross Talk | Lupin India | Topic: Approach of Screening Cardiovascular Risk in T2DM Speaker: Dr. Abhamoni Baro and Dr. Chandan Modak Disclaimer: This program is facilitated by... | By Lupin India | Facebook

3P-MACE including cardiovascular death, myocardial infarction, and... |  Download Scientific Diagram
3P-MACE including cardiovascular death, myocardial infarction, and... | Download Scientific Diagram

3P-MACE: 3-point major adverse cardiac events – All About Cardiovascular  System and Disorders
3P-MACE: 3-point major adverse cardiac events – All About Cardiovascular System and Disorders

3P-MACE Event Rates in CVOTs (Placebo Groups) | Download Scientific Diagram
3P-MACE Event Rates in CVOTs (Placebo Groups) | Download Scientific Diagram

3P-MACE by baseline covariates. The Forest plot shows hazard ratios... |  Download Scientific Diagram
3P-MACE by baseline covariates. The Forest plot shows hazard ratios... | Download Scientific Diagram

Impact of hypoglycemia at the time of hospitalization for heart failure  from emergency department on major adverse cardiovascular events in  patients with and without type 2 diabetes | Cardiovascular Diabetology |  Full Text
Impact of hypoglycemia at the time of hospitalization for heart failure from emergency department on major adverse cardiovascular events in patients with and without type 2 diabetes | Cardiovascular Diabetology | Full Text

Abbreviations 3P-MACE: 3-point major adverse cardiovascular events;... |  Download Scientific Diagram
Abbreviations 3P-MACE: 3-point major adverse cardiovascular events;... | Download Scientific Diagram

Impact of Chronic Kidney Disease on the Associations of Cardiovascular  Biomarkers With Adverse Outcomes in Patients With Suspected or Known  Coronary Artery Disease: The EXCEED‐J Study | Journal of the American Heart
Impact of Chronic Kidney Disease on the Associations of Cardiovascular Biomarkers With Adverse Outcomes in Patients With Suspected or Known Coronary Artery Disease: The EXCEED‐J Study | Journal of the American Heart

Antihyperglycemic Medications for Cardiovascular Disease Risk Reduction
Antihyperglycemic Medications for Cardiovascular Disease Risk Reduction

Alfonso Valle on X: "Efficacy & safety of SGLT2i/GLP-1RA for CV  outcomes: meta-analysis 👥 170930 👉GLP-1RA & SGLT2i ⤵️11% 3P-MACE vs  placebo/DPP-4 👉SGLT2i vs GLP-1RA ⛔️difference in 3P-MACE SGLT2i ⤵️ 24% HF🏥
Alfonso Valle on X: "Efficacy & safety of SGLT2i/GLP-1RA for CV outcomes: meta-analysis 👥 170930 👉GLP-1RA & SGLT2i ⤵️11% 3P-MACE vs placebo/DPP-4 👉SGLT2i vs GLP-1RA ⛔️difference in 3P-MACE SGLT2i ⤵️ 24% HF🏥